Date: 2012-09-10
Type of information: R&D agreement
Compound: new chemical compounds targeting bacterial and viral infections
Company: AstraZeneca (UK) The Broad Institute (USA)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism:
Disease: bacterial infections, viral infections
Details: AstraZeneca and the Broad Institute have announced a collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs. Under the two-year collaboration announced , the two organizations will work together to address this challenge by bringing together deep expertise in bacterial genomics and biochemistry with a unique collection (or \"library\") of chemical compounds and chemical screening capabilities. The chemical library, created at the Broad Institute, comprises 100,000 customized molecules known as Diversity-Oriented Synthesis (DOS) compounds. It is designed to contain molecular shapes and structures not found anywhere else that can hit even the most challenging biological targets.
Under the agreement, screening and hit-to-lead chemistry will take place in the Broad\'s Chemical Biology Platform and AstraZeneca will optimize, develop and commercialize potential compounds from identified, high-quality leads.
Financial terms:
Latest news:
